The forecast period of 2019-2029 may bring immense growth opportunities for the sulfonamide market as the drug continues to cure people of a plethora of diseases and disorders. Sulfonamides are antibiotics which are simply chemical analogs of p-aminobenzoic acid that interfere with folic acid synthesis. They stop the multiplication and growth of bacteria by the prevention of bacterial folic acid synthesis. On the basis of function, the sulfonamide market can be segmented into hypoglycemic, anti-retroviral, anti-protozoal, diuretic, antimicrobial, anti-inflammatory, and anti-cancer.
Discovered by a German pathologist Gerhard Domagk in the 1930s, it has been used as an effective cure for many bacterial diseases and continues to be a boon for such diseases to date. Prontosil was the name of the first-ever sulfonamide that Domagk had discovered. It was a red dye that released an active and colorless antibacterial compound known as sulfanilamide. This compound further led to the formation of various sulfa drugs.
Get Sample Copy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6541
Versatility May Bring Sea Changes in Growth Rate of Sulfonamide Market
Sulfonamides are used across a plethora of applications. For instance, cystic fibrosis can be treated using the blend of two sulfa drugs types, namely sulfisoxazole and erythromycin. These drugs are used to treat staphylococcus aureus and pseudomonas aeruginosa infections in people infected with cystic fibrosis. Sulfonamide monotherapy is also an efficient method for the treatment of urinary tract infections. Therefore, this aspect can prove to be a growth generator for the sulfonamide market. Sulfonamide, when combined with pyrimethamine, is beneficial for treating and suppressing malaria caused due to chloroquine-resistant strains of Plasmodium falciparum.
New research and development activities are leading to discoveries of sulfonamides as great treatment options for various dangerous and harmful diseases that surround the human body. This can prove to be a game-changer for the sulfonamide market. Key players involved in the sulfonamide market are Teva Pharmaceuticals, Sanofi Aventis, Stiefel Laboratories, GlaxoSmithKline, King Pharmaceuticals, Mylan Pharmaceuticals, Pfizer, Par Pharmaceutical, Boehringer Ingelheim Pharmaceuticals, Abbott Laboratories, and Roche Holding AG.
Government Support Also Proving to be Key Growth Factor for Sulfonamide Market
Increased healthcare spending, as well as approvals from the FDA, is leaving a positive impact on the growth rate of the sulfonamide market. For instance, the U.S. Food and Drug Administration approved the use of Daraprim tablets with a combination of sulfonamides to treat toxoplasmosis. This is a deadly infection caused by a parasite known as Toxoplasma gondii, which can cause critical damage to the brain, eyes, or other organs when in the severe stage. It is the leading cause of foodborne illness in the U.S. Therefore, the emergence of such treatment options with sulfonamide blends can trigger great growth for the sulfonamide market.
The usage of sulfonamide in the veterinary industry may also bring steady growth numbers for the sulfonamide market. Clinical use of sulfonamides with a combination of other drugs to treat bacterial infections in dogs, horses, cats, and zoo animals may add growth to the sulfonamide market to a certain extent.
Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6541
Geographically, the sulfonamide market is spread across North America, East Asia, South Asia and Oceania, Europe, the Middle East, and Africa, and Latin America. The use of sulfonamide in developing countries like China and India may fuel the sulfonamide market greatly. The increased demand for sulfonamide across developing regions because of the cost-effectiveness associated with it. In addition, the rising prevalence of bacterial infections in these regions can also prove to be a growth multiplier for the sulfonamide market. A good regulatory structure and awareness among the general population may bring stead growth for North America during the forecast period. Latin America is also expected to bring good growth due to the low cost of sulfonamide.